hydroxyurea has been researched along with Glial Cell Tumors in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 9.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The parallel effects of simvastatin on cell cycle and PKC activity in rat C6 glioma cells were investigated." | 7.69 | PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment. ( Baetta, R; Battaini, F; Bergamaschi, S; Davegna, C; De Renzis, MR; Fumagalli, R; Govoni, S; Soma, MR, 1994) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 7.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 5.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of three chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin)." | 5.06 | Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA; VanGilder, JC, 1989) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " We show here that antisense suppression of WRN in two human glioma cell lines reproduces hallmarks of the drug cytotoxicity profile of WS cells, namely, hypersensitivity to 4-nitroquinoline 1-oxide, camptothecin and hydroxyurea." | 3.72 | The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function. ( Blank, A; Bobola, MS; D Kolstoe, D; Gold, B; Loeb, LA; Meade, EH; Rabinovitch, PS; Silber, JR; Varadarajan, S, 2004) |
| "The parallel effects of simvastatin on cell cycle and PKC activity in rat C6 glioma cells were investigated." | 3.69 | PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment. ( Baetta, R; Battaini, F; Bergamaschi, S; Davegna, C; De Renzis, MR; Fumagalli, R; Govoni, S; Soma, MR, 1994) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| " Before the appearance of CMML, he received a total dose of 2,894 mg of nimustine for the treatment of a pontine glioma over 12 years." | 3.69 | Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14). ( Amemiya, Y; Hatake, K; Miura, Y; Miyata, T; Muroi, K; Saito, M, 1996) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 3.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "The rats implanted with 9L gliosarcoma were dosed orally with hydroxyurea and L-arginine." | 1.35 | Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. ( Black, KL; Espinoza, AJ; Hu, J; Irvin, DK; Ko, MK; Konda, BM; Ong, JM; Sacapano, MR; Shu, Y; Wang, X; Yin, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (60.71) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Yin, D | 1 |
| Wang, X | 1 |
| Konda, BM | 1 |
| Ong, JM | 1 |
| Hu, J | 1 |
| Sacapano, MR | 1 |
| Ko, MK | 1 |
| Espinoza, AJ | 1 |
| Irvin, DK | 1 |
| Shu, Y | 1 |
| Black, KL | 1 |
| Reardon, DA | 1 |
| Egorin, MJ | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Beumer, JH | 1 |
| Lagattuta, TF | 1 |
| Gururangan, S | 1 |
| Herndon, JE | 1 |
| Salvado, AJ | 1 |
| Friedman, HS | 1 |
| Blank, A | 1 |
| Bobola, MS | 1 |
| Gold, B | 1 |
| Varadarajan, S | 1 |
| D Kolstoe, D | 1 |
| Meade, EH | 1 |
| Rabinovitch, PS | 1 |
| Loeb, LA | 1 |
| Silber, JR | 1 |
| Levin, VA | 9 |
| Edwards, MS | 2 |
| Wara, WM | 5 |
| Allen, J | 1 |
| Ortega, J | 1 |
| Vestnys, P | 2 |
| Brock, WA | 1 |
| Trostle-Weige, PK | 1 |
| Williams, M | 1 |
| Meistrich, ML | 1 |
| Wilson, CB | 5 |
| Vestnys, PS | 1 |
| Chicoine, MR | 1 |
| Silbergeld, DL | 1 |
| Soma, MR | 1 |
| Baetta, R | 1 |
| Bergamaschi, S | 1 |
| De Renzis, MR | 1 |
| Davegna, C | 1 |
| Battaini, F | 1 |
| Fumagalli, R | 1 |
| Govoni, S | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| Jaeckle, KA | 1 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Muroi, K | 1 |
| Miyata, T | 1 |
| Saito, M | 1 |
| Hatake, K | 1 |
| Amemiya, Y | 1 |
| Miura, Y | 1 |
| Prados, MD | 3 |
| Larson, DA | 2 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Sneed, PK | 2 |
| Chang, SM | 1 |
| Mack, EE | 1 |
| Krouwer, HG | 1 |
| Chandler, KL | 1 |
| Warnick, RE | 1 |
| Davis, RL | 3 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Gutin, PH | 3 |
| Phillips, TL | 2 |
| Davis, R | 2 |
| Pischer, TL | 2 |
| Irwin, L | 2 |
| Wara, W | 1 |
| Zänker, KS | 1 |
| Stavrou, D | 1 |
| Osterkamp, U | 1 |
| Wriedt-Lübbe, I | 1 |
| Blümel, G | 1 |
| Wayss, K | 1 |
| Mattern, J | 1 |
| Schuhmacher, J | 1 |
| Volm, M | 1 |
| Weaver, KA | 1 |
| Shapiro, WR | 2 |
| Green, SB | 1 |
| Burger, PC | 1 |
| Mahaley, MS | 2 |
| Selker, RG | 1 |
| VanGilder, JC | 1 |
| Robertson, JT | 1 |
| Ransohoff, J | 1 |
| Mealey, J | 1 |
| Strike, TA | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Phuphanich, S | 1 |
| Liu, HC | 1 |
| Da Silva, V | 1 |
| Murovic, J | 1 |
| Choucair, A | 1 |
| Chamberlain, M | 1 |
| Berger, M | 1 |
| Seager, M | 1 |
| Shapiro, JR | 1 |
| Rodriguez, LA | 1 |
| Prados, M | 1 |
| Fulton, D | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| Chastagner, P | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| Whaley, RA | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 1 |
| Cush, S | 1 |
| Biegel, JA | 1 |
| Leslie, DS | 1 |
| Bigner, DD | 1 |
| Bigner, SH | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Sugiura, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea[NCT00387933] | Phase 1 | 37 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxyurea and Glial Cell Tumors
| Article | Year |
|---|---|
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
7 trials available for hydroxyurea and Glial Cell Tumors
| Article | Year |
|---|---|
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Gl | 2009 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
18 other studies available for hydroxyurea and Glial Cell Tumors
| Article | Year |
|---|---|
Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors.
Topics: Administration, Oral; Animals; Arginine; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeabilit | 2008 |
The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function.
Topics: 4-Nitroquinoline-1-oxide; Adenine; Alkylating Agents; Antineoplastic Agents; Apoptosis; Camptothecin | 2004 |
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra | 1984 |
Histone and DNA synthesis in differentiating and rapidly proliferating cells in vivo and in vitro.
Topics: Animals; Animals, Newborn; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Line; DNA Replica | 1983 |
Assessment of brain tumor cell motility in vivo and in vitro.
Topics: Amidines; Animals; Astrocytoma; Brain Neoplasms; Cell Movement; Clone Cells; Cytochalasin B; Fibrone | 1995 |
PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment.
Topics: Animals; Astrocytoma; Cell Cycle; Demecolcine; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 1994 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14).
Topics: Antineoplastic Agents; Bone Marrow; Brain Neoplasms; Child; Chromosome Aberrations; Eosinophilia; Fa | 1996 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Fibrinolysis induced by rat glioma cells. A mitosis-triggered process?
Topics: Animals; Astrocytoma; Cell Line; Dactinomycin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; | 1978 |
[Incorporation of a 131-iodine-deoxycytidine monophosphate protamine complex into the DNA of tumor-bearing rats following partial synchronization with hydroxyurea].
Topics: Animals; Deoxycytidine; DNA, Neoplasm; Glioma; Hydroxyurea; Iodine Radioisotopes; Isotope Labeling; | 1975 |
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle | 1992 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.
Topics: Cell Cycle; Cell Line; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Hydroxyurea; Karyotyping; Mito | 1987 |
Effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and two related compounds on a spectrum of tumors.
Topics: Adenocarcinoma; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Krebs 2; Fibrosarcoma; Glioma; Hydroxy | 1967 |